- Home
- IMTE vs HEPA Comparison
IMTE vs HEPA Comparison
Compare IMTE & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTE
- HEPA
- Stock Information
- Founded
- IMTE 2008
- HEPA 2013
- Country
- IMTE Malaysia
- HEPA United States
- Employees
- IMTE N/A
- HEPA N/A
- Industry
- IMTE Consumer Electronics/Appliances
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- IMTE Consumer Staples
- HEPA Health Care
- Exchange
- IMTE Nasdaq
- HEPA Nasdaq
- Market Cap
- IMTE 4.3M
- HEPA 4.1M
- IPO Year
- IMTE N/A
- HEPA N/A
- Fundamental
- Price
- IMTE $1.29
- HEPA $0.47
- Analyst Decision
- IMTE
- HEPA
- Analyst Count
- IMTE 0
- HEPA 0
- Target Price
- IMTE N/A
- HEPA N/A
- AVG Volume (30 Days)
- IMTE 19.5K
- HEPA 100.9K
- Earning Date
- IMTE 01-28-2025
- HEPA 11-14-2024
- Dividend Yield
- IMTE N/A
- HEPA N/A
- EPS Growth
- IMTE N/A
- HEPA N/A
- EPS
- IMTE N/A
- HEPA N/A
- Revenue
- IMTE $123,337.00
- HEPA N/A
- Revenue This Year
- IMTE N/A
- HEPA N/A
- Revenue Next Year
- IMTE N/A
- HEPA N/A
- P/E Ratio
- IMTE N/A
- HEPA N/A
- Revenue Growth
- IMTE 4.75
- HEPA N/A
- 52 Week Low
- IMTE $1.06
- HEPA $0.43
- 52 Week High
- IMTE $3.84
- HEPA $3.49
- Technical
- Relative Strength Index (RSI)
- IMTE 50.10
- HEPA 42.44
- Support Level
- IMTE $1.22
- HEPA $0.43
- Resistance Level
- IMTE $1.36
- HEPA $0.53
- Average True Range (ATR)
- IMTE 0.08
- HEPA 0.07
- MACD
- IMTE 0.00
- HEPA -0.01
- Stochastic Oscillator
- IMTE 37.09
- HEPA 13.36
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.